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included in the top 10. Next, 185 patients evaluated the importance of 27 attributes 
in the BWS. Effect on disease progression was most important (RIS= 9.6), followed 
by quality of life (9.2), relapse rate (7.8), severity of side effects (7.6), relapse severity 
(7.4), current MS symptoms (7.3), plaque development (7.3), and safety (6.0). Effect 
on disease progression was 1.8 times more important than influence on lifestyle 
(5.3). Subgroup analysis showed that DMD naïve patients found side effect-related 
attributes far more important than DMD experienced patients. ConClusions: 
Using a thorough method, this study reveals that patients value effectiveness and 
unwanted effects most. Also, heterogeneity was observed in different subgroups. 
Clinicians should be aware of the average preference values and that DMD attributes 
are valued differently by different patients. Person-centred clinical decision-making 
would be needed and requires elicitation of individual preferences.
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UsiNg A MixeD MethoDs APProAch to DeveloP A Discrete choice 
exPeriMeNt iN MUltiPle sclerosis
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objeCtives: NICE has suggested that patient preference plays a role in physician 
selection of some Multiple Sclerosis (MS) treatments, but existing patient prefer-
ence surveys are developed using literature rather than patient input. Aims of this 
study were: combine existing literature with patient interviews to develop a dis-
crete choice experiment (DCE) to assess patient preference for MS treatments and 
compare and contrast this information to critically appraise the mixed methods 
approach. Methods: A literature review was conducted to understand patient pref-
erence for attributes of existing MS treatments and inform development of a DCE. 
12 one-to-one telephone interviews were conducted with MS patients. Interviews 
comprised two parts; understanding treatment attributes of importance to patients, 
and detailed cognitive appraisal of the DCE. Team-based framework analysis was 
conducted using interview audio files. Results: Literature and patients interviewed 
generally agreed on key treatment attributes. Although brain lesions were identified 
from literature as a clinical marker, only one patient expressed this as important and 
others either did not understand it or the information was not shared by their clini-
cian. In agreement with literature, patients shared that side effects impacting their 
quality of life were most important, for example fatigue and infection. Feedback on 
the DCE highlighted the importance of consistency between the wording length of 
the attribute level descriptions; patients considered longer descriptions correlated 
with a ‘worse’ level. Interviews also identified questions where language refinement 
was required to improve comprehensiveness. Patients had little knowledge of dis-
ease severity scores contrary to suggestions in the literature, but as disease severity 
was an important concept, this definition was changed. ConClusions: Combining 
patient interviews and existing literature to develop a DCE can have advantages over 
using literature alone: greater confidence that attributes are important to patients, 
early refinement of language and an understanding of patients’ thought processes 
during DCE completion.
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objeCtives: The caregiver-completed Hyperphagia Questionnaire (HQ) is commonly 
used to assess food-seeking behaviours in Prader-Willi syndrome (PWS). A modified 
version, the HQ for Clinical Trials (HQ-CT), was developed and adapted for use in mul-
tinational PWS clinical trials. Methods: The 13-item HQ was reviewed and modified 
based on industry and regulatory standards. The preliminary HQ-CT was included 
in a phase 2 trial; data analysis informed psychometric evaluation and optimal scor-
ing. Further refinements were made following Food and Drug Administration (FDA), 
clinical reviews, and interviews with PWS caregivers in the United States (US). The 
final 9-item HQ-CT was culturally adapted to 10 European languages using industry 
standards for forward-back translation, followed by cognitive debriefing interviews 
(CDIs) with PWS caregivers in target countries to assess content validity. Results: 
Review of the 13-item HQ removed three items to limit content to observable behav-
iours that could change after treatment. Analysis of trial data provided support for 
an HQ-CT composite score (e.g., alpha coefficients ≥ 0.85), as well as the measure’s 
validity and responsiveness. One item was removed based on FDA recommenda-
tion, yielding a 9-item HQ-CT. Interviews with 6 PWS caregivers in the US supported 
content validity. CDIs conducted with 5 PWS caregivers (native-language speakers 
and target-country residents) tested each of the new language translations. Interview 
samples included male and female caregivers, except for the United Kingdom-English 
and the Netherlands-Dutch samples (females only). Respondent ages ranged from 23 
to 64 years across all countries. European caregivers found the HQ-CT content relevant 
and clear. However, there was some difficulty understanding the term ‘hyperphagia’; 
additional text was added to clarify this word. ConClusions: The development of 
the HQ-CT and its adaptation to 10 European languages, with input from 56 caregivers, 
has produced a valuable instrument for assessing food-seeking behaviours in PWS 
clinical trials in the US and Europe.
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A coMPArisoN of stAteD PrefereNces for iNjectABle DiseAse-
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objeCtives: Medication compliance with injectable disease-modifying treatments 
(DMTs) for multiple sclerosis (MS) is sub-optimal, with published compliance rates 
ranging from 27% to 83%. This study quantified MS patients’ preferences for features 
of injectable DMTs, and examined whether non-compliant patients have different 
preferences than compliant patients. Methods: Adults with self-reported physi-
cian-diagnoses of MS in Germany (N= 189), the United Kingdom (UK) (N= 100) and 
France (N= 100) completed an online discrete choice experiment survey. Treatment-
experienced respondents reported their level of compliance with their current (or 
most recent) MS medicine and two groups were created: compliant respondents 
(who reported always taking medicine exactly as prescribed) and non-compliant 
respondents (who reported missing less than half, about half, or more than half of 
doses). Respondents were presented with a series of nine treatment-choice ques-
tions wherein hypothetical treatments were described in terms of six attributes. 
Mixed-logit regression parameters were used to calculate preference weights, or 
utilities, of attribute levels and relative importance or, utility differences, of changes 
in attributes for both the compliant and non-compliant respondents. Wald- and 
t-tests of the differences in preferences were conducted. Results: In Germany, the 
UK and France, 81%, 37%, and 73% of the sample reported being compliant, respec-
tively. The relative importance of delaying disability progression for 3 years was 2.7 
times more important among the compliant group than the non-compliant group 
in Germany and the UK (P< 0.05) and 1.1 times more important in France. Among 
compliant respondents, improvements in injection frequency (from 30 to 2 injections 
per month) relative to this improvement in efficacy were 1.5, 6.0, and 2.6 times more 
important to the non-compliant group than the compliant group in Germany, the UK, 
and France. ConClusions: Reductions in injection frequency are relatively more 
important to non-compliant MS patients than to compliant patients, while delay-
ing disability progression was relatively more important to compliant MS patients.
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oNliNe sUrvey
Mansfield CA1, Thomas N2, Gebben D1
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Genentech, Inc., South San Francisco, 
CA, USA
objeCtives: To estimate patient preferences for relapsing-remitting multiple sclero-
sis (RRMS) treatments Methods: Patients in the United States who reported receiv-
ing a diagnosis of MS from their physician completed a Web-based discrete-choice 
experiment (DCE) survey that included questions on treatment experience and adher-
ence. The survey presented 10 DCE questions in which respondents were asked to 
choose between pairs of hypothetical MS treatment profiles. The profile attributes of 
the treatments were informed by a literature search and clinician input, and tested in 
patient interviews. Attributes included: change in MS progression and years between 
relapses; risk of serious infection; delivery method and frequency of administration; 
and chance of flu-like and gastrointestinal (GI) symptoms. The profiles in the DCE 
questions were based on an experimental design with known statistical properties. 
Random-parameters logit was used to estimate preferences. Results: The sample 
included 301 patients with RRMS: 81% were female; mean age was 54 years; 56% rated 
their disability level as “normal” or “mild”; and 79% reported currently receiving a 
prescription MS treatment. Nineteen percent reported stopping or skipping treatment 
doses due to flu-like symptoms and 9% due to GI symptoms. Respondents placed the 
greatest decision weight on reducing the chance of MS progression and risk of serious 
infection, as well as on the mode and frequency of administration. Followed by daily 
pills, an intravenous (IV) administration every 6 months was preferred over IV every 
month and injections 3 times per week (P < 0.05). Respondents reported being most 
likely to adhere to either daily pills or IV administration every 6 months (39% and 29% 
of patients, respectively). ConClusions: Patients with RRMS reported that treatment 
preferences were influenced by efficacy, reduced side effects, and less burdensome 
modes of administration. Side effects and mode of administration also influenced 
reported likelihood of treatment adherence.
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PrefereNces of PAtieNts with MUltiPle sclerosis for AttriBUtes 
of DiseAse MoDifyiNg DrUgs iN DecisioN-MAkiNg: A NoMiNAl groUP 
techNiQUe AND Best-worst scAliNg
Kremer IE1, Evers SM1, Jongen PJ2, Dowie J3, van der Weijden T1, van de Kolk I4, 
Hiligsmann M1
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objeCtives: More than 10 disease modifying drugs (DMDs) are available for relaps-
ing-remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS). Poor 
adherence to DMDs often results in suboptimal (cost-)effectiveness. Understanding 
patients’ preferences for DMD and incorporating them in clinical decision-making 
can contribute to adherence to DMDs. This study aims first to identify the full spec-
trum of DMD attributes and second to quantify their relative importance among 
patients. Methods: First, 3 focus groups with RRMS patients were conducted using 
a nominal group technique to explore attributes for decision-making. Through indi-
vidual generation and discussion of attributes, a full list was created and patients 
selected their 10 most important attributes. Second, a best-worst scaling (BWS) was 
conducted in a larger RRMS/CIS patient group to prioritize attributes. Attributes’ 
mean relative importance scores (RIS) were obtained with Hierarchical Bayes analy-
sis. Results: Nineteen patients participated in the focus groups. A list of 34 attrib-
utes was derived of which 7 were excluded from the BWS because they were never 
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Iyer R1, Pike J2, Rana J1, Petrillo J1, Lee A1, Jones E2
1Biogen, Cambridge, MA, USA, 2Adelphi Real World, Manchester, UK
bACkgRound: Multiple sclerosis (MS) is an unpredictable disease that can have 
physical, psychological, and social impacts, reducing health-related quality of life 
(HRQoL). objeCtives: To compare the HRQoL in patients initiated on delayed-
release dimethyl fumarate (DMF; also known as gastro-resistant DMF) and prior 
approved interferon β -1a/b or glatiramer acetate (ABCRE) therapies. Methods: 
Data were identified from the Adelphi MS Disease Specific Programme, a cross-sec-
tional study of MS patients in five EU countries and the US. Relapsing Remitting MS 
(RRMS) patients were identified, receiving DMF or ABCRE therapies with treatment 
duration greater than 12 months. HRQoL was assessed using the Hamburg Quality of 
Life Questionnaire in MS (HAQUAMS), consisting of five domains (fatigue/thinking, 
mobility of lower limbs, mobility of upper limbs, social function and mood) in which 
higher scores indicate poorer HRQoL. Inverse-probability-weighted regression-
adjustment estimated average treatment effects (ATEs) on the HAQUAMS across 
DMF and ABCRE cohorts, utilizing a propensity score generated from age, gender, 
EDSS score at current treatment initiation, BMI, duration of current treatment, line 
of therapy, time since MS diagnosis, and number of comorbid conditions. Results: 
A total of 252 (29 DMF, 223 ABCRE) patients completed the HAQUAMS question-
naire. The overall HAQUAMS score was significantly lower in DMF patients com-
pared to ABCRE patients (ATE= -0.45, p< 0.001, vs. 1.95). Significant differences were 
observed in four of the five subscales, as follows: fatigue/thinking (ATE= -0.47, 
p= 0.001, vs. 1.90), lower limb mobility (ATE= -0.43, p= 0.009, vs. 1.84), social function 
(ATE= -0.54, p< 0.001, vs. 2.05), and mood (ATE= -0.45, p< 0.001, vs. 2.40). The ATE for 
upper limb mobility score was not statistically significant (ATE= -0.15, p= 0.075, vs. 
1.38). ConClusions: RRMS patients on DMF had significantly better HRQoL as 
measured by the HAQUAMS, versus RRMS patients on ABCRE therapies.
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A systeMAtic review of the hUMANistic BUrDeN of DiseAse iN 
PAtieNts with fABry DiseAse
Parini R1, Schiffmann R2, Fotheringham I3, Todorova L4
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objeCtives: Fabry disease is a rare, progressive, X-linked lysosomal storage disor-
der caused by deficiency of α -galactosidase A. Multiple major organs are affected, 
impacting on health-related quality of life (HRQoL). Symptomatic disease requires 
lifelong treatment with intravenous enzyme replacement therapy (ERT; two prod-
ucts available), which has been shown to improve long-term outcomes, delay organ 
damage and improve HRQoL. We present the results of a systematic review of the 
humanistic burden of Fabry disease. Methods: We conducted a systematic search 
of MEDLINE, Embase and congress proceedings to identify studies reporting general 
HRQoL in patients with Fabry disease. Results: The search identified 30 relevant 
publications reporting data for ERT-treated and -untreated male and female adult 
and paediatric patients. The majority of studies assessed HRQoL using the 36-item 
Short-Form Health Survey (SF-36; n= 18) and/or 5-dimension European Quality of Life 
instrument (EQ-5D; n= 8). HRQoL was reduced compared with the general population 
(n= 12), and was worse than or similar to other chronic or progressive conditions 
(n= 8); furthermore, HRQoL deteriorated with age (n= 2) and with progressive dis-
ease severity (n= 1). Two clinical trials were identified (one placebo-controlled and 
one open-label) that described HRQoL improvements with ERT (agalsidase alfa). 
There were five analyses of registry data for patients receiving ERT: four studies 
demonstrated sustained HRQoL improvements with up to 5 years of agalsidase 
alfa treatment, and one study reported improvements after 1 and 2 years of agalsi-
dase beta therapy. In two small cohorts, overall HRQoL either improved in all SF-36 
domains after 10 years of ERT (n= 6 patients) or did not significantly decrease over 
7 years of ERT (n= 10 patients). ConClusions: Patients with Fabry disease experi-
ence significant impairment in HRQoL, and the limited available data suggest that 
this improved while on ERT. Further studies are required to quantify treatment-
associated HRQoL outcomes.
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heAlth-relAteD QUAlity of life iN DoUBle-BliND PhAse iii stUDies of 
BrivArAcetAM As ADjUNctive therAPy of PArtiAl-oNset seizUres
Borghs S1, Elmoufti S2
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objeCtives: To assess the effect of brivaracetam (BRV), a new adjunctive therapy of 
partial-onset seizures (POS), on health-related quality of life (HRQoL). Methods: 
Data from three previously reported Phase III trials of BRV in adults with refrac-
tory POS (NCT00490035; NCT00464269; NCT01261325) were pooled. The QOLIE-31-P 
was collected at randomization and after the 12-week treatment period or early 
termination. The QOLIE-31-P is an epilepsy-specific instrument with seven sub-
scales and a Total score ranging from 0 (worse) to 100 (better HRQoL). Mean change 
from baseline to last observation was compared between BRV and placebo using 
ANCOVA controlling for baseline score. Percentages of meaningfully improved 
patients were calculated using published thresholds. Results: There were 422, 
179, 324, and 235 patients in the placebo, BRV 50mg/day, 100mg/day, and 200mg/
day groups respectively. All mean (SD) changes were positive; they were similar for 
placebo and BRV for the Total score (+2.8 [12.7], +3.0 [14.0], +2.4 [14.0], +3.0 [12.1]) 
and most subscale scores. There was a BRV dose response for Energy/Fatigue (lower 
scores), Daily Activities and Seizure Worry (both higher scores). BRV 100mg/day 
showed significantly larger improvements than placebo (+7.3 [24.6] vs +5.0 [23.1]; 
p= 0.044) on the Seizure Worry subscale; this was the only significant result. 43.6%, 
41.7%, and 36.6% of BRV 50mg/day, BRV 100mg/day, 200mg/day patients experienced 
a meaningful improvement in the Total score, respectively; the rate was 38.6% for 
placebo. ConClusions: Changes in HRQoL were small and generally comparable 
objeCtives: Multiple sclerosis (MS) is a chronic progressive neurologic disease 
and one of the most common causes of disability among young adults. Although 
the clinical manifestations and symptoms of MS are diverse, disease severity 
is generally measured by ambulation based Expanded Disease Severity Scale 
(EDSS). While EDSS captures well the level of disability due to the involvement of 
lower extremities and urinary bladder, its ability to capture other aspects such 
as fatigue and mental function are poor. The aim of this study was to explore the 
relationship between two patient-based measures, a self-administered EDSS and 
Multiple Sclerosis Impact Scale (MSIS-29), a psychometrically validated instru-
ment measuring the physical (20 items) and psychological (nine items) impact 
of MS. Methods: In total, 553 Finnish persons with MS (PwMS) drawn from the 
membership register of the national patient association completed a postal sur-
vey, including EDSS and MSIS-29. Results: PwMS at every (0-9) impairment level 
of the EDSS scale were represented. The mean EDSS score was 4.0, indicating 
moderate disability. The physical impact of MS was strongly related to disease 
severity, with the scores ranging from 3.0 in the mildest disease (EDSS 0) to 76.2 
in the most severe disease (EDSS 8 – 9). The psychological impact increased syn-
chronously with the EDSS score in mild disease (EDSS 0 - 3) and peaked at EDSS 
5, declining thereafter from EDSS 5 to 7. In most severe disability (EDSS 8 – 9) the 
psychological impact of MS was equally high as in EDSS 4. ConClusions: The 
subjective physical burden of MS increases steadily with self-assessed disease 
severity, whereas the psychological burden does not go hand in hand with the 
self-assessed severity of the disease.
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objeCtives: The Multiple Sclerosis International Quality of Life (MusiQoL) ques-
tionnaire is a self-administered, measure designed to evaluate the quality of life of 
patients with multiple sclerosis (MS). The MusiQoL was co-developed in 14 coun-
tries. It is composed of 31 items describing nine dimensions (activity of daily living, 
psychological well-being, symptoms, relationships with friends, relationships with 
family, relationships with health care system, sentimental and sexual life, coping, 
and rejection). The objective of this study is to present the challenges faced dur-
ing the translation of the MusiQoL in 57 additional languages representing seven 
language families. Methods: In each country, the translation process (linguistic 
validation) was conducted by a linguistic expert, using either the standard forward/
backward methodology or the adjusted process, including cognitive interviews with 
six patients. The basis for discussion was the concept list developed in collaboration 
with the authors. Results: Semantic and cultural issues emerged during the pro-
cess. First, item 6 (had difficulty with your occupational activities: e.g., integration, 
interruption, limitation…?) could not be literally translated in most of the coun-
tries. Patients had difficulties understanding the words “integration, interruption, 
limitation.” The periphrasis and examples suggested in the concept list had to be 
used in most cases. Examples of solutions will be provided. Second, activities (e.g., 
shopping, going out to a movie, Do-It-Yourself, gardening) described in the original 
had to be adapted to the religious and social context of the target countries. For 
instance, “going out to a movie” had to be replaced by “going to an amusement park” 
in Saudi Arabia, since cinemas are forbidden for religious reasons. Other examples 
will be presented. ConClusions: The initial simultaneous development of the 
MusiQoL in 14 countries minimized the challenges faced during the translation in 
57 additional languages. The collaboration with the developers and the patients’ 
interviews helped to solve the major issues.
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relAPsiNg reMittiNg MUltiPle sclerosis PAtieNts iNitiAteD oN 
orAl DMf rePort A Better QUAlity of life coMPAreD to PAtieNts oN 
PlAtforM therAPies As MeAsUreD By eQ-5D
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bACkgRound: Th EuroQol dimension (EQ-5D) is a widely used, standardised, qual-
ity of life measure producing health profildes, indices and states. objeCtives: 
To assess how people with Multiple Sclerosis (MS) on delayed-release dimethyl 
fumarate (DMF; also known as gastro-resistant DMF) and prior approved interferon 
β -1a/b or glatiramer acetate (ABCRE) therapies rate their quality of life, based 
on responses to the EQ-5D. Methods: Data were identified from the Adelphi 
MS Disease Specific Programme, a cross-sectional study of MS patients in five 
EU countries and the US. Relapsing Remitting MS (RRMS) patients were identi-
fied, receiving DMF or ABCRE therapies with treatment duration greater than 12 
months. General HRQoL was evaluated using the EQ-5D 3 level utility score, a 
standardized instrument providing a simple, generic measure of health, consisting 
of 5 questions measuring dimensions of health states (mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression). A visual analog scale (VAS) is 
also included to measure overall health. Inverse-probability-weighted regression-
adjustment estimated average treatment effects (ATEs) on the EQ-5D across DMF 
and ABCRE cohorts, utilizing a propensity score generated from age, gender, EDSS 
score at current treatment initiation, BMI, duration of current treatment, line of 
therapy, time since MS diagnosis, and number of comorbid conditions. Results: 
A total of 258 (30 DMF, 228 ABCRE) patients completed the EQ-5D questionnaire 
(mean age, 37.4 years; 31% male) with a mean time since diagnosis of 5.57 years. 
There was a significant difference in the EQ-5D utility score between the DMF and 
ABCRE cohorts (ATE: +0.075, p= 0.016, vs. 0.82 for ABCRE). Similarly, the overall VAS 
health reported by patients in the DMF cohort was significantly higher than the 
ABCRE cohort (ATE: +10.84, p< 0.001, vs 74.55 for ABCRE). ConClusions: Patients 
on DMF reported significantly better functioning and quality of life compared with 
ABCRE patients, as measured by the EQ-5D.
